C‐MYC–positive relapsed and refractory, diffuse large B‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy

• Published in: Cancer Vol. 123; no. 22; pp. 4411 - 4418
• Main Authors: Epperla, Narendranath, Maddocks, Kami J., Salhab, Mohammed, Chavez, Julio C., Reddy, Nishitha, Karmali, Reem, Umyarova, Elvira, Bachanova, Veronika, Costa, Cristiana, Glenn, Martha, Calzada, Oscar, Xavier, Ana C., Zhou, Zheng, Hossain, Nasheed M., Hernandez‐Ilizaliturri, Francisco J., Al‐Mansour, Zeina, Barta, Stefan K., Chhabra, Saurabh, Lansigan, Frederick, Mehta, Amitkumar, Jaglal, Michael V., Evans, Andrew, Flowers, Christopher R., Cohen, Jonathon B., Fenske, Timothy S., Hamadani, Mehdi, Costa, Luciano J.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 15.11.2017
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Autografts; B-cell lymphoma; basic helix‐loop‐helix (MYC); Bcl-6 protein; c-Myc protein; Cancer; Cell survival; Confidence intervals; diffuse large B‐cell lymphoma (DLBCL); Drug Resistance, Neoplasm - genetics; Female; Genes, myc; Health risk assessment; Helix-loop-helix proteins (basic); hematopoietic cell transplantation (HCT); Hematopoietic Stem Cell Transplantation; Humans; Lymphocytes B; Lymphoma; Lymphoma, Large B-Cell, Diffuse - genetics; Lymphoma, Large B-Cell, Diffuse - mortality; Lymphoma, Large B-Cell, Diffuse - pathology; Lymphoma, Large B-Cell, Diffuse - therapy; Male; Middle Aged; Myc protein; MYC proto‐oncogene; non‐Hodgkin lymphoma; Oncology; Patients; Recurrence; Remission; Retrospective Studies; Salvage; Salvage Therapy; Survival; Therapy; Translocation; Translocation, Genetic; Transplantation; Treatment Outcome; Young Adult; MYC proto-oncogene; diffuse large B-cell lymphoma (DLBCL); hematopoietic cell transplantation (HCT); non-Hodgkin lymphoma; basic helix-loop-helix (MYC)

BACKGROUND The impact of MYC proto‐oncogene, basic helix‐loop‐helix (MYC) translocations (with or without additional rearrangements involving the B‐cell lymphoma 2 [BCL2] or BCL6 genes) on the response to salvage therapy and survival in patients with diffuse large B‐cell lymphoma (DLBCL) who experie...